Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity

Hearing Research

Volumn 172, Issue 1-2, 2002, Pages 110-117

  Wolters, Francisca L C ^a   De Vocht, Thijn F ^a   Klis, Sjaak F L ^a   Hamers, Frank P T ^a   Smoorenburg, Guido F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cisplatin; Compound action potential; Guinea pig; Melanotan II; Ototoxicity; Protection

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; CISPLATIN; MELANOCORTIN; MELANOTAN II; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ALBINISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROCOCHLEOGRAPHY; ELECTRODE; FEMALE; GUINEA PIG; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; TREATMENT FAILURE;

ACTION POTENTIALS; ADRENOCORTICOTROPIC HORMONE; ALPHA-MSH; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COCHLEA; ELECTRIC STIMULATION; FEMALE; GUINEA PIGS; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC;

EID: 0036805603     PISSN: 03785955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5955(02)00551-8     Document Type: Article

References (39)

1. Bijlsma W.A., Jennekens F.G., Schotman P., Gispen W.H. Neurotrophic factors and regeneration in the peripheral nervous system. Psychoneuroendocrinology. 9:1984;199-215.
2. Campbell K.C.M., Meech R.P., Rybak L.P., Hughes L.F. D-Methionine protects against cisplatin damage to the stria vascularis. Hear. Res. 138:1999;13-28.
3. (4-9) analogue, ORG 2766, on cisplatin ototoxicity in albino guinea pigs. Hear. Res. 144:2000;157-167.
4. Clerici W.J., Hensley K., DiMartino D.L., Butterfield D.A. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear. Res. 98:1996;116-124.
5. Dallos, P., 1973. The Auditory Periphery. Academic Press, New York.
6. (4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear. Res. 106:1997;9-19.
7. De Koning P., Brakkee J.H., Gispen W.H. Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing or return of sensory function. Beneficial effects of melanocortins. J. Neurol. Sci. 74:1986;237-246.
8. De Koning P., Neijt J.P., Jennekens F.G., Gispen W.H. ORG 2766 protects from cisplatin-induced neurotoxicity in rats. Exp. Neurol. 97:1987;746-750.
9. De Oliviera, J.A.A., 1989. Audiovestibular Toxicity of Drugs, Vol. II. CRC Press, Boca Raton, FL.
10. (4-9) analogue in patients with ovarian cancer. New Engl. J. Med. 322:1990;89-94.
11. Hadley, M.E., Hruby, V.J., Blanchard, J., Dorr, R.T., Levine, N., Dawson, B.V., Al-Obeidi, F., Sawyer, T.K., 1998. Discovery and development of novel melanogenic drugs: melanotan-I and -II. In: Borchardt, R.T. (Ed.), Integration of Pharmaceutical Discovery and Development: Case Studies. Plenum Press, New York, pp. 575-595.
12. Hamers F.P.T., Pette C., Bravenboer B., Vecht C.J., Neijt J.P., Gispen W.H. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother. Pharmacol. 32:1993;162-166.
13. (4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs. Eur. Arch. Otorhinolaryngol. 251:1994;23-29.
14. Haskell-Luevano C., Lim S., Yuan W., Cone R.D., Hruby V.J. Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8 and 9 positions. Peptides. 21:2000;49-57.
15. Heijmen P.S., Klis S.F.L., De Groot J.C.M.J., Smoorenburg G.F. Cisplatin ototoxicity and the possibly protective effect of α-melanocyte stimulating hormone. Hear. Res. 128:1999;27-39.
16. Kaltenbach J.A., Church M.W., Blakley B.W., McCaslin D.L., Burgio D.L. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in hamsters. Otolaryngol. Head Neck Surg. 117:1997;493-500.
17. Kamimura T., Whitworth C.A., Rybak L.P. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear. Res. 131:1999;117-127.
18. Klis S.F.L., O'Leary S.J., Hamers F.P.T., De Groot J.C.M.J., Smoorenburg G.F. Reversible cisplatin ototoxicity in the albino guinea pig. NeuroReport. 28:2000;623-626.
19. Klis S.F.L., O'Leary S.J., Wijbenga J., De Groot J.C.M.J., Hamers F.P.T., Smoorenburg G.F. Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose. Hear. Res. 164:2002;138-146.
20. Kohn S., Fradis M., Podoshin L., Ben-David J., Zidan J., Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct. Pathol. 21:1997;289-299.
21. Kopke R.D., Liu W., Gabaizadeh R., Jacono A., Feghali J., Spray D., Garcia P., Steinman H., Malgrange B., Ruben R.J., Rybak L.P., Van De Water T.R. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otolaryngol. 18:1997;559-571.
22. Laurell G., Bagger-Sjöbäck D. Degeneration of the organ of Corti following intravenous administration of cisplatin. Acta Oto-Laryngol. (Stockh.). 111:1991;891-898.
23. Meech R.P., Campbell K.C.M., Hughes L.P., Rybak L.P. A semiquantative analysis of the effects of cisplatin on the rat stria vascularis. Hear. Res. 124:1998;44-59.
24. Meyer zum Gottesberge, A.M., 2000. Hormonal regulation of the inner ear. In: Sterkers, O., Ferrary, E., Dauman, R., Sauvage, J.P., Tran Ba Huy, P. (Eds.), Menière's Disease 1999 - Update. Kugler, The Hague, pp. 49-57.
25. Nakai Y., Konishi K., Chang K.C., Ohashi K., Morisaki N., Minowa Y., Morimoto A. Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol. 93:1982;227-232.
26. Reser D.H., Rho M., Dewan D., Herbst L., Li G., Stupak H., Zur K., Romaine J., Frenz D., Goldbloom L., Kopke R., Arezzo J., Van De Water T.R. L- and D-methionine provide equivalent long-term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology. 20:1999;731-748.
27. Rybak L.P., Whitworth C., Somani S.M. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope. 109:1999;1740-1744.
28. Schiöth H.B., Muceniece R., Larsson M., Mutulis F., Szardenings M., Prusis P., Lindeberg G., Wikberg J.E.S. Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. Eur. J. Pharmacol. 319:1997;369-373.
29. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 103:1993;1-52.
30. Smoorenburg G.F., De Groot J.C.M.J., Hamers F.P.T., Klis S.F.L. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann. N.Y. Acad. Sci. 884:1999;192-210.
31. Stengs C.H.M., Klis S.F.L., Huizing E.H., Smoorenburg G.F. Cisplatin-induced ototoxicity; electrophysiological evidence of spontaneous recovery in the albino guinea pig. Hear. Res. 111:1997;103-113.
32. Stengs C.H.M., Klis S.F.L., Huizing E.H., Smoorenburg G.F. Cisplatin ototoxicity. An electrophysiological dose-effect study in albino guinea pigs. Hear. Res. 124:1998;94-107.
33. (4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs. Hear. Res. 124:1998;108-117.
34. Ter Laak, M.P., 1999. Putative Pharmacotherapeutical Strategies in the Treatment of Peripheral Neuropathies. Ph.D. thesis, University of Utrecht, Utrecht.
35. Ugwu S.O., Blanchard J., Nguyen L.D., Hadley M.E., Dorr R.T. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm. Drug Dispos. 15:1994;383-390.
36. Van der Zee C.E., Brakkee J.H., Gispen W.H. Putative neurotrophic factors and functional recovery from peripheral nerve damage in the rat. Br. J. Pharmacol. 103:1991;1041-1046.
37. Wilson J.F., Harry F.M. Release, distribution and half-life of α-melanotrophin in the rat. J. Endocrinol. 86:1980;61-67.
38. Wessels H., Gralnek D., Dorr R., Hruby V.J., Hadley M.E., Levine N. Effect of an α-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 56:2000;641-646.
39. Yang Y., Dickinson C., Haskell-Luevano C., Grantz I. Molecular basis for the interaction of [Nle4,D-Phe7] Melanocyte stimulating hormone with the human melanocortin-1 receptor (Melanocyte α-MSH receptor). J. Biol. Chem. 272:1997;23000-23010.